Krasniqi, E.
Barchiesi, G.
Pizzuti, L.
Mazzotta, M.
Venuti, A.
Maugeri-SaccĂ , M.
Sanguineti, G.
Massimiani, G.
Sergi, D.
Carpano, S.
Marchetti, P.
Tomao, S.
Gamucci, T.
De Maria, R.
Tomao, F.
Natoli, C.
Tinari, N.
Ciliberto, G.
Barba, M. http://orcid.org/0000-0001-9050-2917
Vici, P.
Article History
Received: 18 June 2019
Accepted: 25 September 2019
First Online: 29 October 2019
Ethics approval and consent to participate
: Not applicable
: This is not applicable for this review.
: EK, GB, MM, GS, PM, AV, MMS, ST, FT, NT, GC, MB declare no conflicts of interest. LP received travel grants from Eisai, Roche, Pfizer, and Novartis and speaker fees from Roche, Pfizer, Novartis, and Gentili. GM received travel grants from Celgene, MSD, Lilly, Roche, AstraZeneca, and BMS. SC received travel grants from MSD, Lilly, Roche, and Astra Zeneca. DS received travel grants from Roche, Pharma Mar, and Astra Zeneca and personal fees from Roche. RDM declares to be a scientific advisory board member at Exosomics SpA (Siena IT), Hibercell Inc. (New York, USA), Kiromic Inc. (Houston, TX, USA), and at Exiris Inc. (Rome, IT). TG received travel grants from Eisai, Roche, Pfizer, and Novartis and speaker fees/advisory boards from Roche, Pfizer, Novartis, Gentili, and Lilly. CN received travel grants/personal fees from Pfizer, EISAI, Novartis, Merck Sharp & Dohme, and AstraZeneca. PV received travel grants from Eisai, Roche, Pfizer, and Novartis and speaker fees/advisory boards from Roche, Pfizer, Novartis, and Gentili.